Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
NCT06483100
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study is unique because it combines different therapies to see how well they work together in treating the disease. Here are some key points about the study:
- The treatment involves using a combination of drugs that target the cancer cells in different ways.
- Patients will receive the treatment in a specific setting, which allows for close monitoring of their health and response to the therapy.
- The study aims to find out if this combination can improve outcomes compared to standard treatments.
- Researchers are also looking at how well patients tolerate the treatment and any side effects that may occur.
- This study includes a diverse group of participants, which helps ensure that the findings are applicable to a wide range of patients.
- By focusing on a combination of therapies, the study hopes to enhance the effectiveness of treatment and potentially lead to better long-term results.
Third Opinion AI Generated Synopsis
Trial Summary
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
